ANGLE PLC (LON:AGL) said that a study at the University Hospital Ghent, Belgium showed its liquid biopsy system Parsortix consistently harvested oesophageal cancer cells in patients suffering from the disease.
These are the first published results in this cancer type, said ANGLE, and means the Parsortix system is now validated in 24 cancer types in 28 independent cancer research centres located across 11 countries.
Researchers in Belgium utilised ANGLE’s marker-independent Parsortix system to isolate epithelial circulating tumour cells (CTCs) in patients and then performed cell-based image analysis to compare cell morphology and characteristics.
“The study validated how this workstream could be utilised for downstream molecular analysis of cancer biomarkers from single CTCs in a future study, ANGLE added.
Oesophageal cancer is a deadly disease with 80% patient mortality at 5 years from diagnosis, partly due to late diagnosis of the illness.
The research has been published as a peer-reviewed publication PLoS One and may be accessed via https://angleplc.com/library/publications/.
Andrew Newland, ANGLE chief executive, said: “Treatment selection for oesophageal cancer remains a major unmet medical need and we are pleased that this study demonstrates the promise of the Parsortix system in improving the outcomes for these patients.
“We believe that additional studies focused on clinically relevant mesenchymal CTCs, which can be captured and analysed using the Parsortix system, are urgently needed and we look forward to the Ghent team progressing their work in this hard-to-treat cancer type.”